Search results for "hypertrophy"

showing 10 items of 335 documents

Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension.

1999

We investigated the influence of major cardiovascular risk factors (smoking, hypercholesterolemia, diabetes mellitus) on the association between angiotensin-converting enzyme (ACE) gene insertion (I)/deletion (D) polymorphism and echocardiographic left ventricular mass in 225 patients with sustained hypertension, assessed by ambulatory blood pressure monitoring. When the study population was analyzed as a whole, the 3 ACE genotypes did not differ in left ventricular mass (II, 47 g/m2.7; ID, 49 g/m2.7; DD, 51 g/m2.7; p = NS). No difference was found in subjects (n = 135) in whom at least 1 major cardiovascular risk factor was present (II, 51 g/m2.7; ID, 51 g/m2.7; DD: 52 g/m2.7; p = NS). In …

Malemedicine.medical_specialtyAmbulatory blood pressureGenotypeHeart VentriclesPeptidyl-Dipeptidase ALeft ventricular hypertrophyPolymerase Chain ReactionMuscle hypertrophyRisk FactorsInternal medicineDiabetes mellitusmedicineHumansRisk factorAllelesRetrospective StudiesPolymorphism Geneticbiologybusiness.industryAngiotensin-converting enzymeOdds ratioDNABlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseasePrognosisEchocardiography DopplerCardiovascular DiseasesHypertensionCardiologybiology.proteinPopulation studyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessGene DeletionFollow-Up Studies
researchProduct

Impact of metabolic syndrome on left ventricular mass in overweight and obese hypertensive subjects

2007

BACKGROUND: Metabolic syndrome (MS) has been associated with an increased left ventricular (LV) mass in recent reports. Little is known about the association of MS with LV mass (LVM) in overweight and obese individuals. The aim of our study was to investigate the relation between MS and LVM in a population of overweight and obese hypertensive subjects. METHODS: 289 non-diabetic essential hypertensives with a body mass index >25 kg/m2, were enrolled. In all subjects routine blood chemistry, echocardiographic examination and 24-h ambulatory blood pressure monitoring were performed. RESULTS: In the group of overweight patients, participants with MS (n=58), when compared to those without it (n=…

Malemedicine.medical_specialtyAmbulatory blood pressurePopulationOverweightEssential hypertensionBody Mass IndexRisk FactorsInternal medicinemedicineHumansObesityeducationmetabolic syndrome left ventricular mass hypertensionMetabolic Syndromeeducation.field_of_studyChi-Square Distributionbusiness.industryBody WeightMiddle AgedOverweightmedicine.diseaseEchocardiography DopplerCross-Sectional StudiesEndocrinologyBlood pressureBlood chemistryHypertensionLinear ModelsCardiologyFemaleHypertrophy Left VentricularMetabolic syndromemedicine.symptomCardiology and Cardiovascular MedicinebusinessBody mass indexInternational Journal of Cardiology
researchProduct

Upregulation of Phospholipase D Expression and Activation in Ventricular Pressure-Overload Hypertrophy

2005

Evidence for a role of phospholipase D (PLD) in cellular proliferation and differentiation is accumulating. We studied PLD activity and expression in normal and hypertrophic rat and human hearts. In rat heart, abdominal aortic banding (constriction to 50% of original lumen) caused hypertrophy in the left ventricle (as shown by weight index and ANP expression) by about 15% after 30 days without histological evidence of fibrosis or signs of decompensation and in the right ventricle after 100 days. The hypertrophy was accompanied by small increases of basal PLD activity and strong potentiation of stimulated PLD activity caused by 4β-phorbol-12β,13α-dibutyrate (PDB) and by phenylephrine. The mR…

Malemedicine.medical_specialtyBlotting WesternCardiomegalyBiologyGene Expression Regulation EnzymologicMuscle hypertrophyRats Sprague-DawleyDownregulation and upregulationInternal medicinePhospholipase DVentricular PressuremedicineAnimalsHumansRNA MessengerPhenylephrineProtein Kinase CProtein kinase CPharmacologyReverse Transcriptase Polymerase Chain ReactionPhospholipase DPLD2lcsh:RM1-950Body WeightRatsReceptors AdrenergicUp-RegulationEnzyme ActivationIsoenzymeslcsh:Therapeutics. Pharmacologymedicine.anatomical_structureEndocrinologyVentricleVentricular pressureMolecular Medicinelipids (amino acids peptides and proteins)Signal Transductionmedicine.drugJournal of Pharmacological Sciences
researchProduct

Osteogenesis imperfecta: a clinical study of the first ten years of life.

1992

One hundred twenty-seven children with osteogenesis imperfecta (O.I.) were studied during the first 10 years of life. According to Sillence, 40 patients were assigned to type I, 39 to type III, and 48 to type IV O.I. Centiles for height, weight, and the annual number of fractures could be established for the different types of O.I. The development of the skeletal changes could be documented for the different forms of the disease. At birth, the skeletal changes were significantly more severe in type III than in type IV patients. During the first 10 years of life the number of fractures, extent of skeletal deformities, and growth retardation did not differ between types III and IV. Only fract…

Malemedicine.medical_specialtyDentinogenesis imperfectaEndocrinology Diabetes and MetabolismPoison controlShort statureBone and BonesClinical studyFractures BoneEndocrinologymedicineHumansOrthopedics and Sports MedicineLongitudinal StudiesInsulin-Like Growth Factor IChildHemihypertrophyBone Developmentbusiness.industryBody WeightInfant NewbornInfantOsteogenesis Imperfectamedicine.diseaseBody HeightSurgeryRadiographyScoliosisOsteogenesis imperfectaMotor SkillsChild PreschoolOrthopedic surgeryKidney stonesFemalemedicine.symptombusinessCalcified tissue international
researchProduct

Relationship between transforming growth factor beta1 and progression of hypertensive renal disease.

2002

In this study the role of circulating transforming growth factor beta1 (TGFbeta1) on progression of renal hypertensive disease has been investigated. Fifty consecutive outpatients with essential hypertension were enrolled and divided into three groups, according to their urinary albumin excretion (UAE). Group A comprised 10 hypertensives with UAEor=20 mg/24 h (normoalbuminuric group); Group B included 21 hypertensives with UAE20300 mg/24 h (microalbuminuric group); Group C encompassed 19 hypertensives with UAEor= 300 mg/24 h (proteinuric group). In all patients UAE by immunonephelometric assay, circulating TGFbeta1 by a solid phase specific sandwich ELISA technique, BUN and creatinine by ro…

Malemedicine.medical_specialtyDiastoleLeft ventricular hypertrophyEssential hypertensionStatistics NonparametricMuscle hypertrophyExcretionTransforming Growth Factor beta1chemistry.chemical_compoundTransforming Growth Factor betaInternal medicineInternal MedicinemedicinePrevalenceAlbuminuriaHumansInterventricular septumCreatinineEjection fractionbusiness.industryMiddle Agedmedicine.diseasemedicine.anatomical_structureEndocrinologyHypertension RenovascularchemistryEchocardiographyCardiologyDisease ProgressionRegression AnalysisFemaleHypertrophy Left VentricularbusinessBiomarkersJournal of human hypertension
researchProduct

Administration of L-carnitine and mildronate improves endothelial function and decreases mortality in hypertensive Dahl rats.

2010

Hypertension is a well established risk factor for the development of cardiovascular diseases and increased mortality. This study was performed to investigate the effects of the administration of L-carnitine or mildronate, an inhibitor of L-carnitine biosynthesis, or their combination on the development of hypertension-related complications in Dahl salt-sensitive (DS) rats fed with a high salt diet. Male DS rats were fed laboratory chow containing 8% NaCl from 7 weeks of age. Experimental animals were divided into five groups and treated for 8 weeks with vehicle (water; n = 10), L-carnitine (100 mg/kg, n = 10), mildronate (100 mg/kg, n = 10) or a combination of L-carnitine and mildronate at…

Malemedicine.medical_specialtyEndotheliumSodiumPopulationchemistry.chemical_elementInternal medicineCarnitinemedicineAnimalsHeart HypertrophyCarnitineEndothelial dysfunctionRisk factorSodium Chloride DietaryeducationSurvival ratePharmacologyeducation.field_of_studyRats Inbred Dahlbusiness.industryCardiovascular AgentsGeneral Medicinemedicine.diseaseRatsSurvival RateEndocrinologymedicine.anatomical_structurechemistryHypertensionVitamin B ComplexEndothelium Vascularbusinessmedicine.drugMethylhydrazinesPharmacological reports : PR
researchProduct

Interplay of cardiac remodelling and myocardial stiffness in hypertensive heart disease: a shear wave imaging study using high-frame rate echocardiog…

2019

Abstract Aims To determine myocardial stiffness by means of measuring the velocity of naturally occurring myocardial shear waves (SWs) at mitral valve closure (MVC) and investigate their changes with myocardial remodelling in patients with hypertensive heart disease. Methods and results Thirty-three treated arterial hypertension (HT) patients with hypertrophic left ventricular (LV) remodelling (59 ± 14 years, 55% male) and 26 aged matched healthy controls (55±15 years, 77% male) were included. HT patients were further divided into a concentric remodelling (HT1) group (13 patients) and a concentric hypertrophy (HT2) group (20 patients). LV parasternal long-axis views were acquired with an ex…

Malemedicine.medical_specialtyHeart DiseasesConcentric hypertrophy030204 cardiovascular system & hematologyConcentricLeft ventricular hypertrophy030218 nuclear medicine & medical imaging03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineInternal medicineMitral valvemedicineHumansRadiology Nuclear Medicine and imagingInterventricular septumVentricular remodelingAgedVentricular Remodelingbusiness.industryGeneral Medicinemedicine.diseaseHypertensive heart diseasemedicine.anatomical_structureParasternal lineEchocardiographyHypertensionCardiologyFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessEuropean heart journal. Cardiovascular Imaging
researchProduct

Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease.

2009

To evaluate the prevalence of left ventricular hypertrophy (LVH) and left ventricular geometry in a group of 293 hypertensive patients with stage 2-5 chronic kidney disease (CKD), compared with 289 essential hypertensive patients with normal renal function.All patients underwent echocardiographic examination. Patients on stage 1 CKD, dialysis treatment, or with cardiovascular diseases were excluded.LVH was observed in 47.1% of patients with CKD and in 31.14% of essential hypertensive patients (P0.0001). We found increasingly higher left ventricular diameters, thicknesses, and mass from stage 2 to 5 CKD. Distribution of concentric and eccentric LVH was not different between the two groups. H…

Malemedicine.medical_specialtyHeart diseasePhysiologyRenal functionGuidelines as TopicLeft ventricular hypertrophyMuscle hypertrophyElectrolytesCatecholaminesInternal medicineReninInternal MedicinemedicineDiabetes MellitusPrevalenceHumansLeft ventricular geometrycardiovascular diseasesStage (cooking)AldosteroneAgedbusiness.industryCase-control studyBlood Pressure DeterminationMiddle Agedmedicine.diseaseEchocardiography DopplerItalyCase-Control StudiesCreatinineChronic DiseaseHypertensionCardiologyRegression AnalysisFemaleHypertrophy Left VentricularKidney DiseasesNefropatie croniche ipertrofia ventricolare sinistra ipertensione arteriosaCardiology and Cardiovascular MedicinebusinessKidney diseaseGlomerular Filtration RateJournal of hypertension
researchProduct

Impact of type 2 diabetes on left ventricular geometry and diastolic function in hypertensive patients with chronic kidney disease.

2010

Left ventricular hypertrophy (LVH) and diastolic dysfunction are very common in patients with chronic kidney disease (CKD). Aim of this study was to evaluate the impact of type 2 diabetes on LV geometry and diastolic function in hypertensive patients with CKD. We enrolled 288 Caucasian subjects with hypertension and CKD; of them, 112 had diabetes. Patients with cardiovascular (CV) diseases, glomerular filtration rate (GFR)60 ml min(-1) per 1.73 m(2), dialysis treatment and other major non-CV diseases were excluded. All patients underwent routine biochemical analyses and echocardiographic examination with tissue Doppler imaging (TDI). Patients with diabetes had significantly higher LV wall t…

Malemedicine.medical_specialtyHeart diseasemedicine.medical_treatmentRenal functionType 2 diabetesComorbidityLeft ventricular hypertrophyInternal medicineDiabetes mellitusInternal MedicinemedicinePrevalenceHumansRenal Insufficiency ChronicDialysisAgedUltrasonographyheart diseasesVentricular Remodelingbusiness.industryMiddle Agedmedicine.diseaseleft ventricular hypertrophySurgeryBlood pressureDiabetes Mellitus Type 2diabeteHypertensionCardiologydiastolic dysfunctionFemaleHypertrophy Left Ventricularbusinesschronic kidney diseaseKidney diseaseGlomerular Filtration RateJournal of human hypertension
researchProduct

High Responders to Hypertrophic Strength Training Also Tend to Lose More Muscle Mass and Strength During Detraining Than Low Responders.

2021

Räntilä, A, Ahtiainen, JP, Avela, J, Restuccia, J, Kidgell, DJ, and Häkkinen, K. High responders to hypertrophic strength training also tend to lose more muscle mass and strength during detraining than low responders. J Strength Cond Res 35(6): 1500-1511, 2021-This study investigated differences in individual responses to muscle hypertrophy during strength training and detraining. Ten weeks of resistance training was followed by 6 weeks of detraining in men (n = 24). Bilateral leg press (LP) one-repetition maximum (1RM) and maximal electromyography (EMGs) of vastus lateralis (VL) and vastus medialis, maximal voluntary activation (VA), transcranial magnetic stimulation for corticospinal exci…

Malemedicine.medical_specialtyHigh responderWeight LiftingVastus medialisStrength trainingPhysical Therapy Sports Therapy and RehabilitationElectromyographyMuscle massMuscle hypertrophyInternal medicinehigh and low respondersmedicinestrength trainingHumansOrthopedics and Sports MedicineMuscle StrengthLeg pressMuscle Skeletaldetrainingmedicine.diagnostic_testbusiness.industryElectromyographyResistance TrainingGeneral MedicineHypertrophyLow responderharjoitusvasteEndocrinologylihasmassavoimaharjoittelubusinesshypertrophyhuman activitieslihasvoimaJournal of strength and conditioning research
researchProduct